Background {#Sec1}
==========

*Plasmodium malariae* is the parasite responsible of quartan malaria with the typical periodicity of fever paroxysm observed every 72-h as detailed in a study by Camillo Golgi in 1886, but also described in the fourteenth Century by Dante Alighieri in the *Divine Comedy* (seventeen Canto of the *Inferno*) \[[@CR1]--[@CR3]\]. The parasite is widely distributed in most tropical and sub-tropical areas, with overlapping presence with *Plasmodium falciparum*, especially in sub-Saharan Africa, where it might easily be overlooked if molecular techniques such as polymerase chain reaction (PCR) are not used for diagnosis \[[@CR1], [@CR4]\]. Although it is well known that malaria episodes due to *P. malariae* can occur even after 30--50 years following a previous malaria attack, the mechanism responsible for its persistence and late recurrence still remains a medical mystery \[[@CR5]--[@CR8]\]. The failure to identify hypnozoites in liver biopsy of either human and animals is considered a proof that *P. malariae* is not a relapsing *Plasmodium* species, thus still giving the Bignami's interpretation of endo-erythrocytic persistence of the parasite as the more satisfactory \[[@CR3], [@CR8]--[@CR10]\]. However, the fact that the existence of *P. malariae* hypnozoites has never been proven is not "per se" a proof against it. For instance *Plasmodium ovale* is credited to produce hypnozoite although *P. ovale* hypnozoites have never been demonstrated biologically. Herein it is described a case of *P. malariae* infection in an Italian man occurring 5 months after a previous malaria episode despite the fact he had not travelled to a malaria-endemic region. A review of similar cases is also described together with possible explanation of this phenomenon.

Case presentation {#Sec2}
=================

A 52-year-old Italian man sought care at the Emergency Department (ED) of Luigi Sacco Hospital in Milan, Italy on 14 December, 2017, complaining of a quartan pattern of fever that started 1 week before together with arthralgia and myalgia. He reported frequent trips to sub-Saharan Africa, the last one to Mozambique and several previous malaria attacks treated by himself using quinine. He reported to have not taken anti-malarial chemoprophylaxis. A chest X-ray was negative and laboratory examinations were unremarkable except for an increase of C reactive protein (50.9 mg/L) and mild thrombocytopaenia (153,000/µL). A blood smear was negative for malaria parasites as well as a rapid diagnostic test (RDT), but species-specific PCR turned positive for *P. malariae*. He was treated with a standard regimen of oral chloroquine phosphate (1 g per os initially, 500 mg 6 h after the first dose, and then 500 mg once a day on the 2nd and 3rd days of therapy). Subsequently he was in good health until the end of April when fever recurred spiking to 40 °C associated with severe headache. On 4 May, 2018 he presented to the ED of another hospital where a blood smear was positive for trophozoites of *Plasmodium* spp. He was transferred to the ED of L. Sacco hospital where a new blood smear showed scanty trophozoites of *P. malariae*; RDT was negative and species-specific PCR confirmed the diagnosis of *P. malariae*. Clinical examination was remarkable for the presence of *herpes labialis,* but otherwise negative. A chest X-ray was negative and blood examinations showed increase C-reactive protein (201 mg/L) mild anaemia (Hb 12.2 g/dL, Ht 35%), leukopaenia (WBC 3200/μL) and thrombocytopaenia (45,000/μL). In the period between the two *P. malariae* episodes he admitted only a short stay in northern Africa (Libya) without any other trip to sub-Saharan Africa. He was admitted to the Infectious Diseases Ward and treated with a 3-day course of dihydroartemisinin--piperaquine (320/40 mg) 4 tablet/day for 3 days. He was discharged on 8 May, 2018 with negative blood smear and PCR for malaria. On follow-up he had normalization of blood examinations and up to January 2019 no more recurrences of malaria.

Methods {#Sec3}
=======

*Plasmodium malariae* genomic DNA was extracted from 200 μL of whole infected blood samples collected from the patient at both hospital admittances, using PureLink Genomic DNA Kit-Invitrogen. Five microsatellites (MSs) (PM2, PM9, PM11, PM25, PM34) and the antigenic marker *P. malariae* circumsporozoite (*Pmcsp*) gene were genotyped, by PCR amplification and sequencing, in *P. malariae* isolate(s) responsible for the patient's infection in order to compare the primary infection and the second episode.

Microsatellite amplification was performed using specific primers previously described by Bruce et al. \[[@CR11]\], adopting slight modifications in the amplification protocol (Table [1](#Tab1){ref-type="table"}). For amplification of *Pmcsp* gene, two internal primers were designed specifically and used to amplify the central repeat region of the gene (Table [1](#Tab1){ref-type="table"}). All PCR products were examined by gel electrophoresis and sent to Eurofins Genomics Company (Germany) for sequencing. The obtained sequences were compiled and analysed by Accelrys DS Gene Software.Table 1Primers and cycling parameters for PCRPrimersAminoacidsPCR cycling parametersPm09forACG ATA ATA ATA TAA ATG GGG94 °C-30 s, 45 °C-30 s; 72 °C-1 min, 40 cyclesPm09revGTT CAT AAC TTT GAT CTT AACPm11forGGG ATA TGA ATT ACA TAC ACPm11revCTT TAT TTG TGG TCG AGGPm25forCCA AAT AAG TGA CAT ACA ACPm25revGAG GTA ACT TAA AAA ATT CACPm02forGGG GCA TAA AGG AAA AAC94 °C-30 s, 52 °C-30 s; 72 °C-1 min, 40 cyclesPm02revGAA TTT TTG AAT AAC AAG AAA CCPm34forGAA TGG AAA AAT TCC TTC AGPm34revTTG GAC AAT GAA AAA ACT AAGPm MSP1forTTC CAA AAA TTG AGG AAA TGT TPm MSP1revTTT GGA CAA TGT CGG AAC AAPm CSforCCC ACA AAA GCT GTT GAA AAPm CSrevTGG TGA CCA TTC CTC CGT A

Comparison of the genetic diversity of *P. malariae* isolates collected from the patient's two blood specimens collected on first hospital admission (14 December, 2017) and on second admission (5 May, 2018) was performed by direct sequencing of the amplified fragments of six *P. malariae* molecular markers.

A PubMed, Scopus and EMBASE literature search was performed from 1940 to 2018 with the search terms *P. malariae* AND "recrudescence" AND "recurrence" AND "relapse". Several cases were added by cross-referencing the articles cited in the retrieved case reports. Articles in Chinese, Russian and Japanese languages were excluded.

Results {#Sec4}
=======

In each of two tested DNA samples, a single amplified product was observed on agarose gel for each analysed target, suggesting the presence of a single detectable isolate for each malaria episode. The central region of *Pmcsp* gene and three MSs (PM2, PM9, PM34) were successfully sequenced in patient's two blood specimens. The result of the sequencing of PM11 and PM25 showed the amplification of non-specific bands, resulting in a cross-reaction with human DNA, and for this reason these two molecular markers were excluded by the present analysis.

Analysis of polymorphisms of the *Pmcsp* central repeat region resulted in the amplification of a DNA fragment of 864 base pairs (bps) (288 aminoacids) in the isolate responsible of the first episode, with a repeat region characterized by two NDAG tetrapeptide repeat units followed by 51 NAAG tetrapeptide repeat units. The isolate collected from the second episode had a more complex structure of the central repeat region (NDAG~3~ + NAAG~1~ + NAAG~5~ + NDAG~1~ + NAAG~9~ + NDAG~1~ + NAAG~20~) for a total length of 816 bps (272 aminoacids) (Fig. [1](#Fig1){ref-type="fig"}; Additional file [1](#MOESM1){ref-type="media"}: Figure S1).Fig. 1Amino acid sequence alignment of a portion of repeat region of *csp* gene of *P. malariae* isolates analyzed in the present study (Isolate 14-12-17, from first hospital admission; Isolate 05-05-18, from second hospital admission) and of a *P. malariae* isolate from an imported malaria case (*P. malariae* clinical strain)

The sequence analysis of PM2 displayed two different size variants: *P. malariae* isolate collected in December's specimen had an allele size of 192 nucleotides (nts) due to a repeat unit region of 68 nts; instead, the second isolate collected in the second hospital admission showed an allele size of 216 nts with a repeat region of 92 nts (Fig. [2](#Fig2){ref-type="fig"}: Additional file [2](#MOESM2){ref-type="media"}: Figure S2). However, both *P. malariae* isolates collected from the patient displayed the same allele for PM9 (439 nts in size) and PM34 microsatellites (295 nts).Fig. 2Nucleotide sequence alignment of PM2 microsatellite of *P. malariae* isolates analyzed in the present study (Isolate PM 14-12-17, from first hospital admission; Isolate PM 05-05-18, from second hospital admission) and of a *P. malariae* isolate from an imported malaria case (*P. malariae* clinical strain)

Review {#Sec5}
======

Twenty-three case reports of *P. malariae* recrudescence were retrieved from the literature and are summarized in Table [2](#Tab2){ref-type="table"} \[[@CR5]--[@CR7], [@CR12]--[@CR31]\]. However, it is plausible that very ancient case reports written in languages other than English were overlooked by this research by the fact that they are not included in modern databases. The oldest retrieved report about late *P. malariae* recrudescence was published by Shute in 1944 in *The Lancet* and the same author in a review regarding imported malaria in the UK cited another two observed cases occurring after 10 and 15 years \[[@CR12], [@CR32]\].Table 2Case reports of *P. malariae* recrudescenceRef/Author/yearNationalityAge/sexCountry of ResidenceCountry of acquisitionSpecies diagnosisQuartan fever patternPCRInterval between episodesRisk factorTreatment12/Shute/1944Indian26/FUnited KingdomIndia*P. malariae* (Microscopy)NRNo21 yearsNRMepacrine13/Spitler/1948Italian69/MUSAItaly*P. malariae* (Microscopy)YesNo36 yearsNRQuinine14/Lentini/1955Italian70/FItalyItaly*P. malariae* (Microscopy on BM)YesNo45 yearsNRQuinine15/Creyx/1955French56/FFranceMacedonia*P. malariae* (Microscopy)YesNo32 yearsSurgery for hydatidosisQuinine, plasmoquine16/Duggan and Shute/1961English42/MUnited KingdomMyanmar (ex Burma)*P. malariae* (Microscopy)NRNo13 yearsNRPrimaquine5/Guazzi/1963Italian63/FItalyItaly*P. malariae* (Microscopy)YesNo53 yearsSplenectomyNR17/Tsuchida/1982Japanese63/MJapanPapua New Guinea*P. malariae* (Microscopy)YesNo36 yearsSplenectomy, nephrectomySulfa-pyrimethamine, primaquine18/Hess/1993German46/FGermanyKenya*P. malariae* (Microscopy)Yes (2 cycles)No78 and 106 days*P. falciparum* malariaHalofantrine6/Vinetz/1998Greek72/FUSAGreece*P. malariae* (PCR)Yes (5 cycles)Yes40--70 yearsMethotrexate therapyChloroquine7/Chadre/2000Trinidadian70/MTrinidadTrinidad*P. malariae* (Microscopy)Yes (4 cycles)No33 years; possibly 65 yearsNeurosurgeryChloroquine + primaquine19/Skoutelis/2000Greek60/FGreeceGreece*P. malariae* (Microscopy)YesNo45 yearsTreated with chlorambucil and methylprednisolone (suspected myeloproliferative syndrome)Chloroquine20/Morovic/2003Serbian61/MCroatia (Former Yugoslavia)Croatia*P. malariae* (Microscopy)YesNo35 yearsNRChloroquine21/Chim/2004Chinese66/FHong KongChina*P. malariae* (Microscopy)NRNo55 years?SplenectomyChloroquine22/Muller-Stover/2008Nigerian34/MGermanyNigeria*P. malariae* (Microscopy; PCR)NRYes14 weeks*P. falciparum* malariaAtovaquone/proguanil23/Smith/2011Australian59/MAustraliaUganda*P. malariae* (Microscopy)NRNo47 days*P. falciparum* malariaChloroquine24/Hedelius/2011American34/MUSANigeria*P. malariae* (Microscopy; PCR)NRYes14 yearsNR/Concomitant diagnosis of nephrotic syndromeAtovaquone/proguanil25/Franken/2012Kenyan38/FGermanyKenya*P. malariae* (Microscopy; PCR)NRYes4 months*P. falciparum* malariaChloroquine26/Hong/2012Korean23/FKoreaGhana*P. malariae* (Microscopy; PCR)NRYes1 month*P. malariae* malariaFirst episode: chloroquine; second episode: mefloquine27/Liang/2013NR20/FUSAUganda*P. malariae* (Microscopy; PCR)YesYes8 weeks*P. malariae* malariaFirst episode: chloroquine; second episode: atovaquone-proguanil28/Kugasia/2014Sierra Leone65/MUSASierra Leone*P. malariae* (initially misidentified as *P. falciparum*)NoNo25 months*P. malariae* malariaFirst episode: quinine + clindamycin\
Second episode: chloroquine29/Visser/2016DutchNR/MThe NetherlandsUganda*P. malariae* (Microscopy; PCR)NoNo^a^2 months*P. malariae* malariaChloroquine30/Rutledge/2017Ugandan31/MAustraliaUganda*P. malariae* (Microscopy; PCR)NoYes52 days*P. malariae* malariaFirst episode: artemether/lumefantrine\
Second episode: hydroxychloroquine + primaquine31/Islam/2018Ivory Coast23 months/MUSALiberia*P. malariae* (Microscopy; PCR)NoYes4 months*P. malariae* malariaFirst episode: Chloroquine\
Second episode: chloroquine\
Third episode: atovaquone--proguanil*M* male, *F* female, *PCR* polymerase chain reaction, *NR* not reported, *BM* bone marrow^a^PCR was not employed for the recurrence diagnosis

In the oldest cases recorded the diagnosis of *P. malariae* infection was based on microscopy only and the long latency before the recrudescence was inferred by the notion about elimination of malaria in the country of origin or by the last time in which the patients lived in or travelled to an endemic area \[[@CR5], [@CR6], [@CR12]--[@CR17], [@CR19]--[@CR21]\]. No difference of gender was observed in the cases reported in the literature and the median age of patients was 59 years. A quartan fever paroxysm was reported in 73.3% of described cases for whom this information was available (11/15) \[[@CR6], [@CR7], [@CR13]--[@CR15], [@CR17]--[@CR19], [@CR26]\]. Malaria was acquired in Europe (before its elimination) in 7 cases, in sub-Saharan Africa in 11 cases, in Southeast Asia in 3 cases, and in Trinidad in the remaining case. The attack of malaria was precipitated by surgery in five patients (splenectomy in 3 cases), and immunosuppressive therapy in 2 patients \[[@CR5]--[@CR7], [@CR15], [@CR17], [@CR19], [@CR21]\]. An episode of falciparum malaria preceded the recrudescence by *P. malariae* in 4 patients consistent with the possibility of initially overlooked mixed infections \[[@CR18], [@CR22], [@CR23], [@CR25]\]. Six patients had a documented episode of malariae malaria 4 weeks to 25 months before the diagnosis of recrudescence \[[@CR26]--[@CR31]\]. Splenomegaly was documented in 9 patients (36.4%) and in two cases splenectomy was undertaken as diagnostic evaluation \[[@CR5], [@CR6], [@CR14], [@CR18]--[@CR21], [@CR31]\]. At the time of *P. malariae* recrudescence diagnosis, a nephritic syndrome was observed in two patients \[[@CR21], [@CR24]\]. Chloroquine was the drug most frequently employed for treatment (12 patients, 52.2%) followed by quinine (4 patients) \[[@CR6], [@CR7], [@CR13]--[@CR15], [@CR19]--[@CR21], [@CR23], [@CR25]--[@CR31]\].

Discussion {#Sec6}
==========

*Plasmodium malariae* is the most neglected among *Plasmodium* species responsible of human malaria, being frequently undetected due to the very low parasitaemia it causes. Only recently a draft nuclear genome and a high-quality reference genome of *P. malariae* have been made available but nevertheless this *Plasmodium* remains the most mysterious among human malaria parasites and its long-term persistence has so far been elusive to any convincing explanation \[[@CR33], [@CR34]\]. Moreover, the existence among African apes and New World monkeys of two very similar species based on morphologic characteristics (i.e., *Plasmodium rhodaini* and *Plasmodium brasilianum*) has raised the question whether *P. malariae* should be considered a zoonosis, an anthroponosis or as inferred by Lalremruata et al., at least in South America, *P. malariae* and *P. brasilianum* are a single anthropozoonotic species \[[@CR35]--[@CR37]\].

Recurrences of *P. malariae* infection even after more than 50 years of latency have been described in old malaria literature (Table [2](#Tab2){ref-type="table"}) but the availability of molecular biology techniques nowadays allowed a better classification of such episodes as a consequence of recrudescence or re-infection \[[@CR5]--[@CR7], [@CR12]--[@CR31]\].

Herein it is described a case of an Italian man who presented two symptomatic PCR-confirmed episodes of *P. malariae* infection occurring 5 months apart. His medical history was notable for several previous episodes of malaria acquired during his frequent travels to sub-Saharan Africa, usually with self-treatment with quinine. In the interval between the two observed episodes of malaria the patient denied any further stay in endemic areas except for a visit to Libya, a country considered malaria-free, thus giving the hypothesis of a recrudescence as the most plausible. Interestingly, genotyping of four *P. malariae* specific genetic markers indicated substantial genetic diversity of the two *P. malariae* strains responsible for the first and the second malaria episode. In this context the possibility of a de-novo infection acquired in Libya cannot be discarded and the recent description in Italy by Martelli et al. \[[@CR38]\] of two Malian immigrants diagnosed with falciparum malaria in Italy after a long stay (3 to 5 years) in Libya might be concordant with this hypothesis.

Alternatively, in the case of recrudescence, one can consider the possibility of chloroquine-resistance or inadequate drug concentration. To the best of knowledge clinical chloroquine-resistant *P. malariae* has been reported only in a study conducted in Indonesia and in a single anecdotal case acquired in Africa \[[@CR28], [@CR39]\]. In the former study one patient had persistent parasitaemia on day 28 and two had persistent parasitaemia on day 8. However, Collins and Jeffery retrospectively analysed the curve of clearance of *P. malariae* among neurosyphilis patients infected with *P. malariae* and subsequently treated with chloroquine and showed that an extended clearance time is frequent with this species, concluding that is not indicative of resistance to chloroquine \[[@CR40]\].

However, recurrence of *P. malariae* in cases of mixed malaria infections in which *P. malariae* was initially overlooked and the patients were treated for *P. falciparum* infection with mefloquine, halofantrine, quinine, or artemether/lumefantrine (AL) have been previously reported \[[@CR18], [@CR22], [@CR23], [@CR28]\]. More recently, Rutledge et al. \[[@CR30]\] described a late recrudescence of *P. malariae* in which the minority initial subpopulation survived after treatment with AL and they postulated the need to use artemisinin combination therapy (ACT) with long half-life partner drug and longer follow-up of patients with *P. malariae*. Another possibility to be investigated as proposed for *P. falciparum* is the sequential use of two artemisinin-based combination regimens \[[@CR41]\]. As far as the described patient, although the malaria infection was acquired in Africa where a single possible *P. malariae* chloroquine-resistant episode has been described, the decision was to treat the second episode of malaria with dihydroartemisinin--piperaquine (DHP) with no malaria recurrence after 8 months of follow-up \[[@CR26]\]. However, given the long latency described for *P. malariae* infections it is presently unknown for how long a patient should be followed and, in clinical practice, among travellers with imported malaria follow-up longer than 4 weeks seems unfeasible \[[@CR5]--[@CR7], [@CR12]--[@CR17], [@CR19]--[@CR21], [@CR23]\]. More recently, in a study aimed to investigate the biological basis of breakthrough *P. malariae* among travellers using atovaquone--proguanil chemoprophylaxis, Teo and co-workers showed the absence of mutation in the parasite locus *pmcytb* associated with recrudescence of *P. falciparum* \[[@CR42]\]. These investigators hypothesized again the possibility that *P. malariae* is a relapsing parasite with the capacity to undergo latent hypnozoites in the liver responsible of new erythrocytic sexual replication years after the initial infection. Based on the life span of erythrocytes (110 days) and of hepatocytes (150--300 days), Richter et al. \[[@CR43]\] concurred with the hypothesis of the liver as the possible reservoir of *P. malariae*. However, Garnham, based on several observations concluded that "*P. malariae* are recrudescences of persisting blood forms of the respective parasites" \[[@CR3], [@CR8], [@CR44]\].

Moreover, it is hard to explain how a dormant liver parasite is responsible of malaria transmitted by blood transfusion by an asymptomatic blood donor as long as 44 years after the last exposure in a malaria endemic area \[[@CR45]--[@CR47]\]. The interesting report by Rutledge and co-workers who showed that the recrudescent isolate in the patient they described was a single clone present at low density in the initial *P. malariae* infection, raised also the possibility that this patient harboured several different population of *P. malariae* acquired at different time frames with different fitness to anti-malarial drugs, one of which was capable of emerging when the susceptible ones were eliminated \[[@CR30]\].

The review of the literature confirms the importance of immunity in controlling long-term latency of *P. malariae* with a state of balanced parasitism which can be abruptly broken by stress events, such as surgery or removing the spleen or by treatment with immunosuppressive drugs, each one responsible for recrudescence of malaria \[[@CR5]--[@CR7], [@CR15], [@CR17], [@CR19], [@CR21]\]. However, the precipitating event in several other cases remain unexplained \[[@CR12]--[@CR14], [@CR16], [@CR18], [@CR20], [@CR22]--[@CR31]\]. Also intriguing is the ability of *P. malariae* to escape drugs which are blood schizontocidal for *P. falciparum* despite the very low parasitaemia that the former parasite produces. It can be speculated that in view of the long pre-patent period of *P. malariae* the duration of therapy against this *Plasmodium* should be increased and when using an artemisinin combination, as suggested by Rutledge et al., a partner drug that is slowly eliminated should be preferred \[[@CR30], [@CR33]\].

Conclusion {#Sec7}
==========

It is described a case of probable *P. malariae* recrudescence, together with explaining hypothesis and a review of the literature of long-latency recrudescences. One-hundred and sixty-five years after its description *P. malariae* remains the most mysterious of the human malaria parasites and as suggested by Shute "it provides an almost perfect example of successful parasitism, without the frequent change of host need by other species of human malaria" \[[@CR12]\]. Several recent thorough reviews about *P. malariae* persistent parasitism take again the hypnozoite hypothesis based on the fact that the "not proven existence" (as for *P. ovale*) should not be considered as proof for the non-existence of *P. malariae* hypnozoites and the need to search for an alternative place of dormancy, such as the spleen \[[@CR25], [@CR43], [@CR48]--[@CR50]\].

Additional files
================
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**Additional file 1: Figure S1.** Phylogenetic tree inferred from CSP nucleotide sequence alignment obtained from *P. malariae* isolates analyzed in the present study (Isolate PM 14-12-17; Isolate PM 05-05-17) and from 12 representative CSP gene sequences retrieved from the GenBank database. *P. vivax* CSP gene sequence (Genbank accession number AJ295636) was also included in the analysis and used as an outgroup. Phylogenetic analysis was done using the neighbour-joining method constructed using the neighbor-joining method by bootstrapping with 1000 replicates, and phylogenetic distances were measured by Tajima-Nei model, using the Accelrys DS Gene software package (Accelrys Inc., San Diego, CA, USA). **Additional file 2: Figure S2.** Phylogenetic tree inferred from PM2 microsatellite sequence alignment obtained from *P. malariae* isolates analyzed in the present study (Isolate PM 14-12-17; Isolate PM 05-05-17) and from all representative sequences of PM2 microsatellite retrieved from the GenBank database. Phylogenetic analysis was done using the neighbour-joining method constructed using the neighbor-joining method by bootstrapping with 1000 replicates, and phylogenetic distances were measured by Tajima-Nei model, using the Accelrys DS Gene software package (Accelrys Inc., San Diego,CA,USA). Reference: Tajima F, Nei M. Estimation of evolutionary distance between nucleotide sequences. Mol Biol Evol. 1984;1:269--85.
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